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Since disturbed metabolic conditions such as obesity and diabetes can be critical determinants of breast
cancer progression and therapeutic failure, we aimed to determine the mechanism responsible for their
pro-oncogenic effects. Using non-invasive, epithelial-like ERa-positive MCF-7 and T47D human breast
cancer cells we found that hyperglycaemia induced epithelial to mesenchymal transition (EMT), a key
programme responsible for the development of metastatic disease. This was demonstrated by loss of the
epithelial marker E-cadherin together with increases in mesenchymal markers such as vimentin,
ﬁbronectin and the transcription factor SLUG, together with an enhancement of cell growth and invasion.
These phenotypic changes were only observed with cells grown on ﬁbronectin and not with those plated
on collagen. Analyzing metabolic parameters, we found that hyperglycaemia-induced, matrix-speciﬁc
EMT promoted the Warburg effect by upregulating glucose uptake, lactate release and speciﬁc glycolytic
enzymes and transporters. We showed that silencing of fatty acid synthase (FASN) and the downstream
ERa, which we showed previously to mediate hyperglycaemia-induced chemoresistance in these cells,
resulted in suppression of cell growth: however, this also resulted in a dramatic enhancement of cell
invasion and SLUG mRNA levels via a novel caveolin-1-dependent mechanism.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Evidence suggests that breast cancer patients presenting with
metabolic conditions such as obesity and diabetes do not respond
as well to treatment and have a higher overall mortality rate: the
major inﬂuence being hyperglycaemia [1e3]. Otto Warburg in the
1920s [4,5] identiﬁed a distinct metabolic proﬁle of cancer cells
characterised by increased glycolytic activity and lactateEpithelial to mesenchymal
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ehydrogenase; MCT, Mono-
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B.V. This is an open access article uproduction even in the presence of oxygen. The so-called Warburg
effect plays a crucial role in sustaining the increased bioenergetic
and biosynthetic requirements of rapidly proliferating cancer cells
and has been the subject of intense investigations in recent years
[6,7]. Despite the resurgence in interest in cancer cell metabolism
and its recognition as one of the fundamental hallmarks of tu-
mours, the development of effective metabolic interventions to
prevent breast cancer progression remains a continuing challenge.
Death from breast cancer is generally due to the development of
metastatic disease. As many as 30% of patients with early breast
cancer develop metastatic disease with the majority of these being
resistant to current therapies [8]. The metastatic cascade is a
complex multistage event that involves the detachment of cancer
cells from the primary tumour, entry into the blood or lymphatic
system and invasion into a new microenvironment that is condu-
cive to their attachment and subsequent growth. Changes in the
tumour microenvironment including extensive remodelling of
extracellular matrix (ECM) and alterations in the surrounding
stromal cells are strongly associatedwithmalignant transformationnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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ECM has been heavily implicated in the process of tumour devel-
opment, with reports linking elevated ﬁbronectin expression in
breast cancer stroma with tumour aggressiveness and poorer
prognosis [11,12]. The loss of epithelial differentiation referred to as
epithelial to mesenchymal transition (EMT) has been proposed to
contribute to metastatic progression. The downregulation of
epithelial markers (such as E-cadherin), increases in mesenchymal
markers (such as N-cadherin, vimentin and ﬁbronectin) and tran-
scription factors (including SNAIL and SLUG) together with the
acquisition of increased motility, invasion and stem cell properties
are key deﬁning features of the EMT program [13]. While it is
overwhelmingly clear that EMT plays a critical role in cancer pro-
gression and metastasis only a few studies have investigated the
impact of the metabolic status on this process. As such, we wished
to explore the effects of metabolic conditions on EMTwith a view to
identifying potential novel targets for intervention.
In this study, we report that exposure of the estrogen receptor a
(ERa)-positive MCF-7 and T47D human breast cancer cells to high
glucose levels induced EMT; however, this was only observed with
cells grown on ﬁbronectin but not with those plated on the base-
ment membrane component collagen. Furthermore, we show that
hyperglycaemia-induced, matrix-speciﬁc EMT triggered a meta-
bolic switch towards the Warburg effect by upregulating glucose
uptake, lactate release and speciﬁc glycolytic enzymes and trans-
porters. We also attempted to block the hyperglycaemia-induced
EMT phenotype by targeting the lipogenic enzyme fatty acid syn-
thase (FASN) and the downstream ERawhich, as previously shown
by us, cooperate together to mediate hyperglycaemia-induced
chemoresistance in these cells [14,15]. We found that whilst tar-
geting FASN or ERa signalling effectively suppressed cell growth, it
also resulted in enhanced invasive capacity. Mechanistically, these
pro-invasive effects were found to be driven by caveolin-1, a lipid
raft protein implicated in various aspects of tumour progression
including EMT [16e18]. Overall, these novel ﬁndings highlight the
signiﬁcance of the metabolic status as a powerful factor that de-
termines which women have cancers that progress to life-
threatening metastatic disease. Furthermore, we reveal the pro-
invasive consequences of targeted inhibition of FASN and ERa sig-
nalling in ERa-positive breast cancers and we provide evidence for
the therapeutic potential of caveolin-1 in this speciﬁc context.2. Materials and methods
2.1. Cell culture
The human breast cell lines MCF-7, T47-D, MCF10A, ZR-75-1,
MDA-MB-231 and Hs578T were purchased from the American
Type Culture Collection (ATCC, Molsheim, France). All cell lines
were cultured as described previously [14,19]. For all experiments,
cells were seeded onto ﬁbronectin or collagen-coated 6-well plates
at a density of 0.1 106/well in 5mM glucose-containing DMEM
growth media for 24 h and then switched to serum free media
containing different concentrations of glucose including 5mM
(normal, Sigma: D5546), 9 (prepared from 5 and 25mM glucose-
containing DMEM) and 25mM (high glucose, Sigma: D6429) for
48 h in the presence or absence of target siRNA to the ERa, FASN,
caveolin-1 or a non-silencing siRNA or were treated with
anti-estrogens fulvestrant or tamoxifen as outlined before [15]. We
used two different siRNAs to silence ERa, FASN and caveolin-1; we
conﬁrmed the effective knockdown of caveolin-1 using a second
siRNA sequence in the present study (data not shown). All
siRNAs were purchased from Qiagen and their sequences were as
follows: 50-CUGACACUUUAAUUACCAATT-30 and 50-UUGGUAAUUAAAGUGUCAGGA-30 for caveolin-1 siRNA 1, 50-
CAGUCUUCCUGACACUUUATT-30 and 50-UAAAGUGUCAGGAAGA-
CUGGA-30 for caveolin-1 siRNA 2. Fibronectin-coated 6-well plates
were purchased from Greiner Bio-One. Collagen-coated 6-well
plates were prepared according to the manufacturer's protocol
(Sigma).
2.2. Cell growth
Cell growth was assessed via direct count of viable cells in a
haemocytometer using trypan blue as described previously [14].
Changes in cell growth were also conﬁrmed by assessing the pro-
tein abundance of a cell cycle protein cyclin D1 using western
immunoblotting.
2.3. Transwell invasion assay
Cells were seeded onto collagen or ﬁbronectin-coated dishes as
described above. 48 h post-treatment, cells were trypsinised as
described previously [14] and 5 105 cells were seeded into
matrigel pre-coated 8 mm pore transwell inserts (Milipore) in the
corresponding glucose-containing serum free media and allowed
to invade towards medium containing 10% FBS for 24 h. After in-
cubation, cells in the insert (non-invaded cells) were removed with
a cotton swab and invaded cells were ﬁxed and stained with DAPI.
The number of invaded cells was manually quantiﬁed in 5
randomly selected ﬁelds of view under 20 magniﬁcation.
2.4. Western immunoblotting
Western blot analysis was performed as described previously
[14]. Brieﬂy, 20 mg of protein were run on 10% SDS-PAGE, trans-
ferred to nitrocellulose membrane (BioRad) and immunoblotted
with the following antibodies: ﬁbronectin (1:500, BD Biosciences),
E-cadherin (1:1000, Cell Signalling), vimentin (1:500, BD Bio-
sciences), N-cadherin (1:1000, BD Biosciences), FASN (1:1000, BD
Biosciences), ERa (1:750, Santa Cruz), cyclin D1 (1:1000, Santa
Cruz), PARP (1:1000, BD Biosciences), caveolin-1 (1:500, Santa
Cruz), GAPDH (1:5000, Millipore) and tubulin (1:5000, Millipore),
following the manufacturer's instructions. After incubation with
speciﬁc secondary antibodies conjugated to peroxidase (Sigma),
proteins were visualised by Clarity ECL substrate (BioRad) using
BioRad Chemidoc XRS þ system and analysed using Image lab
software (BioRad).
2.5. Glucose uptake and lactate and citrate measurements
After treatments, the cells were washed with PBS and incubated
in Krebs-Ringer bicarbonate (KRB) buffer for 15min at 37 C fol-
lowed by the addition of the non-metabolisable glucose analogue
tritiated 2-deoxyglucose (0.5 mCi per well, PerkinElmer) for 5min.
Subsequently, the cells were washed three times with ice-cold PBS
and then solubilised in 1% (v/v) Triton X-100 in PBS. The incorpo-
rated radioactivity was assessed using a Beckman Scintillation
Counter LS6500. Data were recorded as disintegrations per minute
(DPM). Lactate and citrate levels were measured in cell superna-
tants using colorimetric Lactate Assay and Citrate Assay Kits (Bio-
Vision) following the manufacturer's instructions and the
absorbance was measured using iMark Microplate Absorbance
Reader (BioRad). Data were normalised to protein content.
2.6. qPCR and primers
Total RNA was extracted with Ribozol RNA extraction reagent
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capacity RNA-to-cDNA kit (Life Technologies). qPCR was performed
with SYBR Green JumpStart Tag ReadyMix (Sigma) according to the
manufacturer's protocol using ABI StepOne Plus Real-Time PCR
System (Applied Biosystems, 4376600). Relative mRNA levels were
determined using 2DCt method. The GAPDH gene was used as an
internal control. The primer sequences were taken fromKondaveeti
et al. [20] and their speciﬁcity conﬁrmed by melting curve analysis
(data not shown). All primer pairs were synthesised by Sigma.
2.7. Statistical analysis
Data were analysed with SPSS 12.0.1 for Windows using one-
way ANOVA followed by least signiﬁcant difference (LSD) post-
hoc test. A statistically signiﬁcant difference was considered to be
present at p< .05.
3. Results
3.1. Hyperglycaemia induces EMT in breast cancer cells grown on a
ﬁbronectin substrate
To explore the effects of metabolic conditions on EMT we tested
three concentrations of glucose: 5mM glucose (euglycaemic),
9mM glucose (levels observed in a reasonably controlled diabetic
patient) and 25mM glucose (hyperglycaemic). A localised breast
cancer predominantly interacts with collagen in the basement
membrane but once the cancer has spread it is increasingly exposed
to ﬁbronectin in the adjacent stroma [21]. To mimic these stages of
cancer progression we analysed the effects of exposure to different
levels of glucose on cells grown on collagen and ﬁbronectin. Having
performed the phenotypic characterisation of EMT status in various
breast cancer cell lines (Supplementary Fig. S1) we chose MCF-7
and T47-D cells that exhibited predominantly epithelial charac-
teristics, in all subsequent experiments. Our results showed that
increasing levels of glucose were associated with the promotion of
EMT only in cells cultured on ﬁbronectin and not with those plated
onto collagen. From the lowest to the highest concentration of
glucose we observed signiﬁcant reductions in E-cadherin (p< .05)
and signiﬁcant increases in ﬁbronectin (p< .01), vimentin (p< .05)
and the transcription factor SLUG (p< .05) (Fig. 1a (i-iv) and b). We
next examined changes in cell phenotype such as growth and in-
vasion. As shown in Fig.1c (upper panel), hyperglycaemia induced a
dose-dependent increase in cell growth on both matrices but this
was more marked with cells on ﬁbronectin (1.1 (p< .05) and 1.3
(p< .01) fold increases from 5 to 25mM glucose on collagen and
ﬁbronectin). The level of growth observed at every glucose con-
centration was signiﬁcantly greater with cells exposed to ﬁbro-
nectin in comparison to those on collagen (e.g. 1.6-fold increase at
5mM glucose; p< .01). Consistent with these results, the abun-
dance of the cell cycle protein cyclin D1 mirrored these changes in
growth (Fig. 1c, lower panel). We also showed that on collagen the
level of invasion remained the same regardless of glucose con-
centrations, whereas on ﬁbronectin invasion increased in a dose-
dependent manner (1.4-fold increase from 5 to 25mM glucose;
p< .01; Fig. 1d). We obtained similar results using another non-
invasive epithelial cell line, T47D (Supplementary Fig. S2). We
used uncoated plastic plates as an additional control and we
observed that there was no signiﬁcant difference in the levels of
EMT markers, cell growth and invasion between cells grown on
collagen-coated and uncoated plates (data not shown). We also
conﬁrmed that an osmotic control medium (5mM glucose sup-
plemented to 25mMwithmannitol) did not have any effect on EMT
phenotypic properties in MCF-7 cell line (Supplementary Fig. S3).
These results suggest that exposure of breast cancer cells tohyperglycaemia and a more advanced tumour microenvironment
such as ﬁbronectin promotes EMT.
3.2. Hyperglycaemia-induced EMT phenotype is reversed upon
silencing FASN
FASN is a key enzyme responsible for the synthesis of fatty acids
and a number of clinical reports link its expression with more
aggressive tumour characteristics andworse clinical outcomes [22].
Our earlier work in the MCF-7 and T47D cells identiﬁed FASN as a
keymediator of hyperglycaemia-induced chemoresistance [14]. We
speculated that FASN might be a likely candidate in mediating the
hyperglycaemia-induced, matrix-speciﬁc EMT observed in our cell
model. To explore this, we performed siRNA-mediated knock down
of FASN and assessed its impact on EMT markers, cell growth and
invasion. We did not observe any signiﬁcant change in the protein
levels of FASN during hyperglycaemia-induced, matrix-speciﬁc
EMT with cells grown on ﬁbronectin. Whilst we cannot rule out an
increase in FASN enzyme activity we previously found that inhib-
iting FASN signalling by either siRNA or through administration of
C75, an inhibitor of FASN activity, had the same effect [14]. Exam-
ining the expression of EMT markers, we found that silencing FASN
reversed the hyperglycaemia-induced EMT phenotype leading to
increased expression of E-cadherin (p< .05) and decreased
vimentin (p< .01) and ﬁbronectin (p< .01) (Fig. 2a (i-v)). These
changes in EMT markers were still glucose-dependent but in the
opposing direction when FASN expression was silenced. The
changes in mRNA levels for SLUG were not only dose-dependently
reversed with respect to glucose but also greatly upregulated in
FASN silenced cells when compared to the non-silencing control (3-
fold increase at 5mM glucose with FASN knocked-down; p< .01;
Fig. 2b). While FASN knock-down resulted in the suppression of cell
growth and a dose-dependent reversal in the effects of glucose on
EMT markers, we observed a dramatic stimulation of cell invasion
at every glucose concentration (e.g. 2.8-fold increase in invasion at
5mM glucose with FASN knocked down; p< .01; Fig. 2d). Whilst
these results suggest that FASN plays a key role in EMT and cell
growth under hyperglycaemic conditions, as these were inhibited
when FASN was silenced, our data also indicates that silencing
FASN enhanced their invasive ability.
3.3. Effect of hyperglycaemia-induced, matrix-speciﬁc EMT on
metabolic parameters
We found that hyperglycaemia-induced, matrix-speciﬁc EMT
led to a 1.5-fold increase in glucose uptake (comparing 5 to 25mM
glucose; p< .05; Fig. 3a) that was associated with upregulation of
glucose transporter 12 (GLUT12) mRNA (2-fold increase from 5 to
25mMglucose; p< .05) but not that of GLUT1 or GLUT4 (Fig. 3b and
Supplementary Fig. S4). Lactate production was also signiﬁcantly
elevated in cells undergoing EMT (1.5-fold increase from 5 to
25mM glucose; p< .05) compared to the control cells grown on
collagen that were unaffected by the levels of glucose (Fig. 3c); this
was accompanied by a parallel increase in the lactate dehydroge-
nase A (LDHA) mRNA levels (2-fold increase from 5 to 25mM
glucose; p¼ .01; Fig. 3d), an enzyme which converts pyruvate to
lactate. Furthermore, the levels of the lactate monocarboxylate
exporter 4 (MCT4) mRNA and that of the lactate importer MCT2
mRNA increased by 1.7-fold (p< .05 and p¼ .05 respectively) dur-
ing hyperglycaemia-induced, matrix-speciﬁc EMT. (Fig. 3e (i&ii)).
Levels of citrate that correspond to activity of the tricarboxylic acid
(TCA) cycle increased with rising glucose levels when the cells were
grown on collagen but were relatively decreased during
hyperglycaemia-induced EMT in the cells grown on ﬁbronectin
when compared with cells grown on collagen thereby conﬁrming
Fig. 1. Exposure of breast cancer cells to hyperglycaemia and ﬁbronectin induces EMT. (a, i) MCF-7 cells were cultured as described in Materials and methods section. Western
blotting was performed to examine the protein abundance of the indicated EMT markers. (a, ii) Densitometry was performed to quantify the protein levels of EMT markers. (b) SYBR
green-based qPCR analysis of SLUG mRNA levels. (c) Changes in cell growth were assessed by direct count of viable cells in a haemocytometer (upper panel) and assessment of
cyclin D1 protein expression by Western blotting (lower panel). (d) Cell invasion was measured using the transwell assay. In all cases, results shown are representative of three
independent experiments, each performed in triplicate and are expressed as means of ±SEM. (For interpretation of the references to color in this ﬁgure legend, the reader is referred
to the Web version of this article.)
Fig. 2. Silencing of FASN results in the reversal of hyperglycaemia-induced, matrix-speciﬁc EMT phenotypic properties and enhanced cell invasion. Changes to the
hyperglycaemia-induced EMT phenotype following siRNA-mediated knockdown of FASN were assessed by (a) western blot analysis of EMT markers, (b) quantiﬁcation of SLUG
mRNA levels by qPCR, (c) cell counting and (d) transwell invasion assay. Results shown are representative of three separate experiments, each performed in triplicate. Data are
represented as mean± SEM. (NS¼ non-silencing).
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Fig. 3. Hyperglycaemia-induced, matrix-speciﬁc EMT triggers a metabolic switch towards the Warburg effect. (a) Glucose uptake was assessed using the non-metabolisable
glucose analogue, tritiated 2-deoxyglucose, in MCF-7 cells with or without FASN silenced with siRNA. The mRNA levels of the indicated metabolic enzymes were detected using
SYBR green-based QPCR as shown in b, d, e, g and h. Lactate and citrate levels were measured in cell supernatants using colorimetric based assays (c and f). In all cases, results
shown are representative of three independent experiments, each performed in triplicate and are expressed as means of ±SEM. (For interpretation of the references to color in this
ﬁgure legend, the reader is referred to the Web version of this article.)
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ﬁbronectin (Fig. 3f). Citrate levels increased in a glucose dependent
manner on both substrates. Knock down of FASN completely sup-
pressed the EMT associated changes in all of these metabolic pa-
rameters to the same degree regardless of the glucose
concentration (Fig. 3aef). To extend our metabolic analysis, we also
analysed the mRNA levels of key enzymes related to anabolic
pathways essential for macromolecular biosynthesis including
phosphoglycerate dehydrogenase (PHGDH), an enzyme involved in
the serine biosynthesis pathway, enzymes of the pentose phos-
phate pathway (glucose-6-phosphate dehydrogenase: G6PD,
transketolase: TKT, and transaldolase 1: TALDO1) and hexosamine
biosynthetic pathway (glutamineefructose-6 phosphater-
ansaminase: GFPT1). The mRNA levels of all of these enzymes
except PHGDH were unaffected by glucose levels on either matrix
(Fig. 3g and Supplementary Fig. S5). PHGDH mRNA expression
increased in a glucose-dependent manner in cells cultured on
ﬁbronectin (1.5-fold increase from 5 to 25mM glucose; p< .05) in
comparison to those on collagen that were unaffected by the levels
of glucose (Fig. 3h). PHGDH and TALDO1 mRNA were signiﬁcantly
suppressed following FASN knockdown on ﬁbronectin to the same
degree in all levels of glucose. These results clearly suggest that
hyperglycaemia-induced EMT on ﬁbronectin triggers a metabolic
switch towards the Warburg effect with increased glucose uptake
predominantly via the GLUT12 transporter, increased lactate pro-
duction along with upregulation of enzymes and transporters for
lactate (i.e., LDHA and MCT2 and MCT4), increased serine biosyn-
thesis and a concurrent downregulation of TCA cycle activity.
3.4. Antiestrogens fulvestrant and tamoxifen exacerbate
hyperglycaemia-induced EMT phenotypic properties irrespective of
the metabolic status
ERa is known to regulate and contribute to the Warburg effect
in breast cancer cells [23]. Furthermore, we recently showed that
ERa functions as a downstream effector of FASN in the context of
hyperglycaemia-induced chemoresistance [15]. Given that tar-
geting FASN during hyperglycaemia-induced, matrix-speciﬁc EMT
was clearly not a good therapeutic approach, as it increased the
invasive potential of the cells, we next determined whether tar-
geting downstream ERa signalling would have a similar effect. We
blocked ERa signalling using two anti-estrogenic agents, fulves-
trant and tamoxifen, that are in clinical use and compared this
with silencing the ER using siRNA and assessed any modiﬁcations
to hyperglycaemia-induced EMT changes. At the doses described
previously (0.1 mM fulvestrant and 1 mM tamoxifen) [15], we
conﬁrmed that fulvestrant downregulates the ERa and tamoxifen
stabilises it as reported in the literature (Fig. 4a (i&ii)) [24]. Fig. 4a
(iii) shows that, downregulation of the ERa using either fulves-
trant or the siRNA to ERa which mimicked the effects of fulves-
trant treatment induced a glucose-independent reduction in E-
cadherin and a strong increase in vimentin (Fig. 4a (iv)) and
ﬁbronectin (Fig. 4a (v)). A similar trend, although to a much
smaller extent was observed in MCF-7 cells treated with tamox-
ifen (Fig. 4a (iii-v)). Quantiﬁcation of SLUGmRNA levels revealed a
dramatic increase in SLUG expression following treatment with
fulvestrant and the ERa siRNA and to a lesser extent by exposure
to tamoxifen (ERa siRNA: 13-fold increase at 25mM glucose;
p < .01, fulvestrant: 15-fold increase at 25mM glucose; p < .01,
tamoxifen: 3.3-fold increase at 25mM glucose; p < .05) (Fig. 4b).
We also observed that the effect of glucose varied with each
treatment: while there was a glucose-dependent increase in SLUG
mRNA with ERa siRNA, with fulvestrant the levels of SLUG mRNA
remained the same irrespective of glucose concentration whereas
with tamoxifen the effect of glucose appeared to be reversed.Next, we assessed the growth and invasive potential of these cells.
Suppression of ERa signalling by siRNA or antiestrogens signiﬁ-
cantly reduced the growth rate to comparable levels although
there still remained a glucose-dependent increase with ERa siRNA
and tamoxifen but not with fulvestrant (Fig. 4c, upper panel). The
inhibition of cell growth was not a result of apoptosis, as we did
not observe an induction of poly(ADP-ribose) polymerase (PARP)
cleavage with any treatment (Fig. 4c, lower panel). When analysed
for their invasive potential, cells treated with either agent dis-
played signiﬁcantly higher and comparable invasive capacity
compared to the control cells; although this increased invasive
activity was then unaffected by the levels of glucose (e.g. ERa
siRNA: 2.2-fold increase at 5mM glucose; p < .05, fulvestrant: 2.4-
fold increase at 5mM glucose; p < .01, tamoxifen: 2.5-fold in-
crease at 5mM glucose; p < .01) (Fig. 4d). As shown in Fig. 4eei,
we observed a strong downregulation of all glycolytic compo-
nents upon treatment with both antiestrogens and the siRNA to
ERa. With the exception of MCT2 mRNAwhose levels increased in
a glucose-dependent manner upon treatment with ERa siRNA
other metabolic parameters appeared to follow a similar glucose-
independent pattern with all treatments. Taken together, these
ﬁndings indicate that the current therapeutic strategies using
fulvestrant and tamoxifen could result in a more invasive
phenotype irrespective of the metabolic status.
3.5. Caveolin-1 mediates the pro-invasive properties triggered by
FASN or ERa silencing during hyperglycaemia-induced, matrix-
speciﬁc EMT
Caveolin-1 is a lipid raft protein that plays a key role in the
regulation of signal transduction pathways and cholesterol trans-
port and recently several studies have shown that caveolin-1
functions as an important regulator of EMT [16,17]. We observed
that the protein levels of caveolin-1 were dramatically increased
upon FASN or ERa knock down by siRNA and following treatment
with antiestrogens fulvestrant and tamoxifen when compared to
the non-silencing control: cells displayed the most dramatic in-
crease in caveolin-1 with FASN and ERa silenced (4.8 and 4-fold
increase at 5mM glucose with FASN and ERa knocked down;
p< .01 and p< .01 respectively (Fig. 5a (i&ii)). Much higher protein
levels of caveolin-1 were also observed in the highly invasive ERa-
negative MDA-MB-231 and Hs578T cells when compared to the
non-metastatic ERa-positive MCF-7 and T47D cells, indicating a
strong correlation between caveolin-1 expression and breast can-
cer aggressiveness (Supplementary Fig. S6). We therefore assessed
whether knock-down of caveolin-1 by speciﬁc siRNA is sufﬁcient to
prevent the increase in SLUG mRNA levels and cell invasion trig-
gered by fulvestrant; because of the striking phenotypic similarity
across different levels of glucose we decided to perform our
experiment only under hyperglycaemic conditions. We found that
silencing caveolin-1 blocked the ability of fulvestrant to increase
cell invasion and SLUG mRNA levels when compared to the non-
silencing control (Fig. 5b and c). Effective caveolin-1 silencing is
indicated in Fig. 5d (i&ii). Taken together, these results identify
caveolin-1 as a critical modulator of the pro-invasive phenotype
induced by fulvestrant during hyperglycaemia-induced, matrix-
speciﬁc EMT.
4. Discussion
The role of metabolism in breast cancer has come to the fore-
front over the last few years owing to the global epidemic in obesity
and diabetes and its strong connection with breast cancer. A
recently conducted meta-analysis reported a 23% increase in risk of
developing breast cancer and a 38% rise in mortality risk among
Fig. 4. Inhibition of ERa during hyperglycaemia-induced, matrix-speciﬁc EMT results in a more metastatic phenotype irrespective of the glucose concentration. (a, i) Protein
expression of EMT markers following downregulation of ERa signalling by siRNA or anti-estrogens fulvestrant (0.1 mM) and tamoxifen (1 mM). (a, ii) The densitometry measurements
from the western blot are shown. (b) Quantiﬁcation of SLUG mRNA levels as determined by qPCR. (c, upper panel) Cell growth was assessed as described above. (c, lower panel)
Western blot detection of PARP cleavage was used as an indicator of apoptosis. (d) Cell invasion was measured as described above. (eei) Changes to the metabolic parameters
following ERa knock down by siRNA and treatment with antiestrogens were assessed as described in the legend of Fig. 3. Results shown are representative of three independent
experiments, each performed in triplicate. Data are represented as mean± SEM. (NS¼ non-silencing).
H.A. Zielinska et al. / Cancer Letters 419 (2018) 187e202194
Fig. 4. (continued).
H.A. Zielinska et al. / Cancer Letters 419 (2018) 187e202 195breast cancer patients with diabetes [25]. Another study found that
obesewomen had a 55% greater risk of developing postmenopausal
breast cancer [26]. A strong association between metabolic condi-
tions and more aggressive tumour characteristics has also been
well-documented [2]. The discovery of the EMT program was a
major breakthrough in our understanding of the process of
metastasis- the ultimate cause of death in more than 90% of breast
cancer patients. However, the impact of metabolic status on EMTand that of EMTon themetabolism of cancer cells has received little
attention.
We provide evidence that exposing epithelial breast cancer cells
to high levels of glucose and ﬁbronectin, that is associated with an
advanced cancer microenvironment, promotes breast cancer pro-
gression by driving EMT. Speciﬁcally, we report that these micro-
enviromental conditions induce an EMT protein signature, activate
SLUG and promote cell growth and invasion. The context-
Fig. 4. (continued).
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Paget's ''seed and soil'' theory, which suggests that cancer cells,
referred to as the ''seeds'', are intimately linked to their local
microenvironment, called the ''soil'' [27]. We have identiﬁed that
hyperglycaemia and ﬁbronectin exposure provide a favourable
microenvironment that induces EMT together with increases in
growth and invasion and further enhanced the Warburg effect.
With respect to the latter, we observed that hyperglycaemia-
induced, matrix-speciﬁc EMT was associated with a signiﬁcant in-
crease in glucose uptake predominantly via the GLUT12 trans-
porter, higher levels of lactate secretion along with upregulation of
the LDHA enzyme and MCT2 and MCT4 lactate carriers and
decreased dependency on oxidative phosphorylation (OXPHOS).
Similar metabolic changes were recently reported by Kondaveeti
et al. in two independent breast cancer cells lines forced to undergo
EMT by prolonged mammosphere culture conditions [20]. In that
study, the authors also reported substantial increase in glycolytic
activity of the cells in response to EMT, as demonstrated by
increased glucose uptake, lactate secretion and upregulation of
glucose and lactate transporters. In another study, genetic silencing
of the respiratory enzyme citrate synthase led to induction of the
Warburg effect, EMT and increased metastases in a mouse xeno-
graft model [28]. The crucial contribution of the matrix to EMT has
also been documented before. In line with our study, Park and
Schwarzbauer demonstrated that exposure to ﬁbronectin but not to
matrigel was responsible for transforming growth factor b (TGFb)-
induced EMT in non-transformed MCF10A breast epithelial cells
[29].
To understand the mechanism of hyperglycaemia-induced,
matrix-speciﬁc EMT we focused on our previously deﬁned signal-
ling pathway implicating FASN and the downstream ERa in the
regulation of hyperglycaemia-induced chemoresistance [15]. We
found that silencing FASN reversed the effects of hyperglycaemia
on the levels of EMT markers leading to increased expression of E-
cadherin and decreased vimentin and ﬁbronectin. Similar obser-
vations were recently made by Jungin et al. in both in vitro and
in vivomodels using MCF-7 cells overexpressing mitogen-activated
protein kinase 5 (MCF-7-MEK5)where inhibition of FASN signalling
with a pharmacological agent cerulenin reversed EMT and pro-
moted mesenchymal to epithelial transition (MET) [30]. We found
that inhibiting ERa signalling by either siRNA or using more clini-
cally relevant approaches using the antiestrogens fulvestrant and
tamoxifen resulted in a reduction in E-cadherin and strong in-
creases in ﬁbronectin and vimentin irrespective of the levels of
glucose. We observed that tamoxifen was the least efﬁcient in this
respect, perhaps reﬂecting its different mode of action.
Most importantly, we show that whilst targeting both FASN and
the ERa effectively suppressed cell growth, they also resulted in
enhanced invasive capacity with an associated increase in SLUG
mRNA levels. FASN has long been recognised as an attractive target
for cancer as its inhibition has antiproliferative effects in cancer
cells [31] and the antiestrogens fulvestrant and tamoxifen are the
most common therapeutic approaches for inhibiting ERa signalling
in ER-positive breast cancer patients. However, our ﬁndings add to
the growing debate over the clinical beneﬁts of these therapeutic
drugs. In agreement with our study, Borley and co-workers recently
showed that fulvestrant and tamoxifen promote an invasive
phenotype in E-cadherin deﬁcient MCF-7 cells by activating Src
kinase [32] and others have found that these endocrine agentsFig. 5. Silencing of caveolin-1 prevents the increase in cell invasion and SLUG mRNA leve
i&ii) Western blot analysis of caveolin-1 protein expression after siRNA-mediated silencing
(b) The invasive capacity induced by fulvestrant was assessed in MCF-7 cells with or withou
caveolin-1 knock-down on the fulvestrant-induced SLUG mRNA levels as determined by q
Results shown are representative of three independent experiments, each performed in trimodulate cell invasion via distinct mechanisms [33]. Furthermore,
tamoxifen treatment has been reported to induce the expression of
matrix metalloproteinases (MMPs) [34], the well-known ECM-
degrading enzymes that participate in tumour invasion [35]. As
such, the results reported by us and others shed some light on the
current issue of breast cancer recurrence associated with admin-
istration of these therapeutic agents [36]. Targeting FASN has also
been proposed but likewise needs careful consideration. Stable
knock down of FASN in non-obese diabetic/severe combined im-
munodeﬁciency (NOD/SCID) mice injected with A549 non-small
cell lung cancer cells resulted in increased metastatic spread to
lymph nodes, colon, liver and thymus and decreased overall sur-
vival [37]. This study is consistent with our ﬁndings indicating that
silencing FASN correlates with increased invasive potential of the
cells despite the reduction in cell growth.
In terms of the metabolic phenotype, we observed a consider-
able glucose-independent suppression of all glycolytic components
upon treatment with both antiestrogens and the siRNA to the ERa
and FASN, most likely reﬂecting the activation of different meta-
bolic pathways. It has in fact been pointed out by a number of in-
vestigators that cancer cells within a tumour display a remarkable
ability to switch between different metabolic phenotypes
depending on the microenviromental challenges and/or treatment
modalities to which they are exposed [38], [39]. Even more sig-
niﬁcant are the ﬁndings that such metabolic plasticity is a hallmark
of highly aggressive tumours [40]. A study by O'Mahony and col-
leagues has shown that estrogen can modulate the ability of MCF-
7 cells to switch between different metabolic pathways depending
on glucose availability [41]. In colorectal cancer cells, stable knock-
down of FASN led to a signiﬁcant decrease in glycolytic capacity
[42].
Inhibiting FASN and the ERa was associated with increased
invasive capacity and we observed that this was associated with a
dramatic up-regulation of caveolin-1. Caveolin-1 is located in
plasma membrane invaginations called caveolae: in addition to the
presence of caveolin-1, they are also characterised by an abundance
of sphingolipids, and cholesterol. Caveolin-1 is considered to play a
key role in the regulation of cellular cholesterol homeostasis [43].
Our mechanistic studies identiﬁed caveolin-1 as the major driver of
the pro-invasive phenotype triggered by targeting FASN or the ERa
during hyperglycaemia-induced, matrix-speciﬁc EMT. Silencing of
caveolin-1 using siRNA blocked the ability of fulvestrant to induce
the cell invasion that was accompanied by a reduction in SLUG
mRNA levels. Caveolin-1 is highly expressed in invasive breast
cancer cells consistent with reports linking caveolin-1 expression
with tumour aggressiveness and poorer prognosis [44,45] and
more recently caveolin-1 has been shown to play a role in EMT
[17,18]. Given the emerging role of caveolin-1 in breast cancer
progression, our ﬁndings raise the possibility of exploiting
caveolin-1 as a therapeutic target to prevent invasion or as a clinical
biomarker. As a proof of concept, a previous study showed that
inhibition of caveolin-1 signalling by siRNA or caveolin scaffolding
peptide in inﬂammatory breast cancer cells resulted in a reduction
in invasive potential in an Akt1-dependent manner [46].
We identiﬁed that caveolin-1 mediated the increased invasion
when FASN and ERawere inhibited. A recent discovery that the 27-
hydroxycholesterol biosynthetic pathway is involved in the regu-
lation of resistance to estrogen deprivation in ERa-positive breast
cancer cells [47] may be linked to the way in which caveolin-1ls triggered by fulvestrant during hyperglycaemia-induced, matrix-speciﬁc EMT. (a,
of FASN or ERa and following treatment with antiestrogens fulvestrant and tamoxifen.
t caveolin-1 knocked down with siRNA using transwell invasion assay. (c) The effect of
PCR. (d, i&ii) Caveolin-1 knock-down efﬁciency was determined by western blotting.
plicate. Data are represented as mean± SEM.
Fig. 6. A schematic diagram illustrating the proposed mechanism of caveolin-1-mediated increase in invasion observed upon silencing FASN/ERa during hyperglycaemia-
induced, matrix-speciﬁc EMT. Exposure to hyperglycaemia and ﬁbronectin induces EMT and further enhances the Warburg effect by upregulating glucose uptake, lactate release
and speciﬁc glycolytic enzymes and transporters. Inhibiting FASN/ERa signalling suppresses the glycolytic phenotype and promotes invasion via upregulation of caveolin-1 in lipid
rafts also enriched in cholesterol and various signalling proteins and receptors. Considering the direct involvement of caveolin-1 in mediating cellular cholesterol homeostasis this
pro-invasive phenotype is potentially associated with a metabolic shift from glycolysis to cholesterol biosynthetic pathway.
H.A. Zielinska et al. / Cancer Letters 419 (2018) 187e202200mediates the induction of invasion observed when we targeted the
FASN/ERa pathway in an attempt to inhibit hyperglycaemia-
induced, matrix-speciﬁc EMT in breast cancer epithelial cells. If
we assume that this is indeed the case then the acquisition of the
pro-invasive phenotype under these experimental conditions
might be explained using a very simpliﬁed model in which inhi-
bition of ERa and FASN signalling during hyperglycaemia-induced,
matrix-speciﬁc EMT triggers the upregulation of caveolin-1 in lipid
rafts which in turn activates signalling pathways that lead to
increased synthesis and possibly accumulation of cholesterol in a
population of residual cancer cells surviving the ERa and FASN
knock-down (Fig. 6). The hypothesis that these highly invasive cells
have used up all available glucose and activate the cholesterol
reservoir to maintain this pro-invasive state is very intriguing and
so is the concept that these changes might be transient.
Collectively, our study strengthens the clinical connection be-
tween metabolic conditions and breast cancer progression by
providing a novel mechanistic insight underlying this association.
We established that hyperglycaemia and exposure to ﬁbronectin
has a major inﬂuence on inducing EMT and further promoting the
Warburg effect: two processes that are intimately linked. Our data
raise concerns regarding targeting the FASN/ERa signalling
pathway in ERa-positive breast cancers as inhibiting them
enhanced the invasive potential of the cells via a novel caveolin-1-
dependent mechanism. If caveolin-1 acts as a pro-invasive switch
combined downregulation of caveolin-1 and FASN/ERa signallingmight be necessary to effectively suppress cell growth and prevent
invasion in a speciﬁc subset of ERa-positive breast cancer patients.
Translating our in vitro data to show the therapeutic potential of
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